Protein Summary
Chromatin-binding protein that converts stress signals into a program of gene expression that empowers cells with resistance to the stress induced by a change in their microenvironment. Interacts with MSL1 and inhibits its activity on histone H4 'Lys-16' acetylation (H4K16ac). Binds the RELB promoter and activates its transcription, leading to the transactivation of IER3. The NUPR1/RELB/IER3 survival pathway may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. In breast cancer cells, NUPR1 overexpression leads to the activation of PI3K/AKT signaling pathway, CDKN1A/p21 phosphorylation and relocalization from the nucleus to the cytoplasm, leading to resistance to chemotherapeutic agents, such as doxorubicin.
- ENST00000324873
- ENSP00000315559
- ENSG00000176046
- ENST00000395641
- ENSP00000379003
- COM1
- P8
- COM1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
small molecule perturbation | 0.98 | ||
virus perturbation | 0.97 | ||
PubMedID | 0.93 | ||
transcription factor perturbation | 0.91 | ||
biological process | 0.84 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 130.51 (req: < 5)
Gene RIFs: 79 (req: <= 3)
Antibodies: 139 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 130.51 (req: >= 5)
Gene RIFs: 79 (req: > 3)
Antibodies: 139 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 15
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0